DUBLIN – U.K. biotech and pharmaceutical industry leaders are hopeful that their hard work in trying to ensure the U.K. maintains its position at the heart of Europe's system of drug regulation is starting to pay dividends. Read More

Sienna Biopharmaceuticals Inc., a California-based dermatology company developing small-molecule topical therapies for people with a variety of common skin issues, is seeking gross proceeds of up to $74.8 million in an IPO. Read More

Two groups reported that vaccinating melanoma patients with personalized, tumor-specific antigens led to progression-free survival in the majority of patients over roughly two years of follow-up. The results were reported in back-to-back papers in the July 6, 2017, issue of Nature. Read More

LONDON – Glaxosmithkline plc (GSK) has become the latest pharma to buy into artificial intelligence (AI) as a means to increase productivity in discovery, signing a £33 million (US$42.6 million) contract under which Exscientia Ltd. will apply its technology to design 10 preclinical candidates against targets nominated by GSK. Read More

GUANGZHOU, China – China's health care reforms have made great strides toward developing the country's pharmaceutical industry, but the current ecosystem may not be enough for China to compete on the world stage of drug development, said industry experts and regulators at this week's GF Securities Life Sciences Investment Conference. Read More

Allergan plc, of Dublin, agreed to pay $13 million to the U.S. and 19 states to resolve a whistleblower lawsuit alleging it engaged in a kickback scheme, according to the attorneys representing the whistleblowers. Read More

Array Biopharma Inc., of Boulder, Colo., submitted two new drug applications to the FDA to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily for the treatment of those with BRAF-mutant advanced, unresectable or metastatic melanoma. Read More

Noxxon Pharma NV, of Berlin, said the first patient had been treated in a phase I/II trial testing NOX-A12 (olaptesed pegol) in patients with metastatic colorectal and pancreatic cancer. Read More

Anaeropharma Science Inc., of Tokyo, secured $13.2 million in new capital to fund advancement of drug candidates targeting hypoxic microenvironments of tumors by using genetically enhanced bacteria. Read More